Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours - Wikidata - wikimedia - TriplyDB

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

http://www.wikidata.org/entity/Q34746009

about

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

P2860

Q26765289-709C5048-ED5F-4B74-8A55-609AC486EB47 Q33918145-359EB747-C2D5-42D5-83A9-13EA2EA26E11 Q33948026-C196BDF1-2C5F-406E-9537-AC349D9478BA Q34414279-DF391691-0726-403E-A204-FA1A9E0E311F Q36708349-5BD03B9A-5DDD-4D7B-B783-C9D88A423445 Q37988794-69AEFC4B-8CCF-41C8-A124-65C3A2A706F4 Q40853524-15FCE2BC-E563-4FE8-90B4-924E2AFE47A4 Q55395981-79340E6C-9D3F-4A4B-B144-F9AD8B429F48

P2860

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

http://www.wikidata.org/entity/Q34746009

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II study of single agent ...... creatic neuroendocrine tumours

@ast

Phase II study of single agent ...... creatic neuroendocrine tumours

@en

Phase II study of single agent ...... creatic neuroendocrine tumours

@nl

type

label

Phase II study of single agent ...... creatic neuroendocrine tumours

@ast

Phase II study of single agent ...... creatic neuroendocrine tumours

@en

Phase II study of single agent ...... creatic neuroendocrine tumours

@nl

prefLabel

Phase II study of single agent ...... creatic neuroendocrine tumours

@ast

Phase II study of single agent ...... creatic neuroendocrine tumours

@en

Phase II study of single agent ...... creatic neuroendocrine tumours

@nl

P1433

Q34746009-195E3727-3F57-45FF-A7F4-A8A34118384F

P1476

Q34746009-CEA49921-2960-4C3C-9CE1-8E1A61B772B6

P2093

Q34746009-34FA8C31-592F-454D-A319-0186DD2F30E7

Q34746009-41F0C71E-E2AD-4858-998B-5B77C1C00EF3

Q34746009-88F62579-5C57-40E2-A3D0-F35C02C03836

Q34746009-9FF03964-93D7-4510-914B-6D50A5D08D8A

Q34746009-A23C1A52-7602-4269-923F-34DF3C97CE17

Q34746009-A9CB7B70-370D-4B8A-A6E5-8C696A9EA0FD

Q34746009-AF18E26B-AE2D-4FD5-86C7-229ED03DDBB5

Q34746009-DF819633-C164-4D69-90FA-6BD8049B6C40

P2860

Q34746009-019822A2-BE7E-4C7F-B341-B12048432859

Q34746009-1FC452AE-4024-40B6-BC0A-9BBD3B6C3EBE

Q34746009-279E36D2-2298-442A-B9D2-27B9C69AB8B9

Q34746009-2D2AE3FD-E450-4C77-AABE-E61EB415982F

Q34746009-2DEA96C0-D91F-48CD-B33C-CEF5CE9383A4

Q34746009-3A3DFE39-168D-48C6-B72A-7A41B5854DC8

Q34746009-47E80728-C2C4-46BF-A5C7-CC1214960DE8

Q34746009-86A77981-6008-4935-905B-C2A2458611BF

Q34746009-914B0A30-8D07-4206-AF9A-F32BA8D272A6

Q34746009-9DB4C07E-11F6-400B-877D-07AD8B293DA2

P2888

Q34746009-FFEAC601-8D82-4A1B-BFDF-F7B53930594E

P304

Q34746009-BFE01723-0E08-4B1C-B21D-25F0F993BA02

P31

Q34746009-F4B6E74F-8A25-4671-9279-A19E0AB0C508

P356

Q34746009-0AF317E8-9254-4EBE-8F36-7708C17CADA7

P407

Q34746009-B63016DD-E689-490B-9374-1B0A99D64722

P433

Q34746009-F805BD2B-BB98-45AF-AEA2-3575EE5D3688

P478

Q34746009-81BE4763-A5B6-4C03-A1BE-9749AE7576F1

P50

Q34746009-A5A9836A-2637-473E-963D-29031E6D3A5A

P577

Q34746009-82CAC070-38D1-4470-9B7E-D366576018CC

P5875

Q34746009-C3819AE1-9F38-4D3B-AFC2-3FA0E578F2C7

P6179

Q34746009-4F8DAEE8-9310-43EA-8524-E415AEEFD108

P698

Q34746009-61F0C00A-63FA-4DB0-8577-10497C44765F

P932

Q34746009-45BE6669-BC03-4F98-BCFF-5295A3FC7739

P356

P1433

British Journal of Cancer

P1476

Phase II study of single agent ...... creatic neuroendocrine tumours

@en

P2093

A N Morel

http://www.w3.org/2001/XMLSchema#string

D C Talbot

http://www.w3.org/2001/XMLSchema#string

D Farrugia

http://www.w3.org/2001/XMLSchema#string

J M Davies

http://www.w3.org/2001/XMLSchema#string

L Medley

http://www.w3.org/2001/XMLSchema#string

N Hayward

http://www.w3.org/2001/XMLSchema#string

N Reed

http://www.w3.org/2001/XMLSchema#string

O Kirichek

http://www.w3.org/2001/XMLSchema#string

P2860

Gastroenteropancreatic neuroendocrine tumours

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.

Diagnosis and treatment of gastric neuroendocrine tumours.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

P2888

P304

1067-1070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.76

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50348960

http://www.w3.org/2001/XMLSchema#string

P6179

1037746402

http://www.w3.org/2001/XMLSchema#string

P698

21386841

http://www.w3.org/2001/XMLSchema#string

P932

3068509

http://www.w3.org/2001/XMLSchema#string